Estados Unidos - inglês - NLM (National Library of Medicine)

hospira, inc. - isoleucine (unii: 04y7590d77) (isoleucine - unii:04y7590d77) - isoleucine 462 mg in 100 ml

Estados Unidos - inglês - NLM (National Library of Medicine)

hospira, inc. - isoleucine (unii: 04y7590d77) (isoleucine - unii:04y7590d77) - isoleucine 561 mg in 100 ml

Estados Unidos - inglês - NLM (National Library of Medicine)

baxter healthcare corporation - valine (unii: hg18b9yrs7) (valine - unii:hg18b9yrs7), lysine acetate (unii: ttl6g7liwz) (lysine - unii:k3z4f929h6), histidine (unii: 4qd397987e) (histidine - unii:4qd397987e), isoleucine (unii: 04y7590d77) (isoleucine - unii:04y7590d77), leucine (unii: gmw67qnf9c) (leucine - unii:gmw67qnf9c), phenylalanine (unii: 47e5o17y3r) (phenylalanine - unii:47e5o17y3r), threonine (unii: 2zd004190s) (threonine - unii:2zd004190s), methionine (unii: ae28f7pnpl) (methionine - unii:ae28f7pnpl), tryptophan (unii: 8duh1n11bx) (tryptophan - unii:8duh1n11bx), alanine (unii: of5p57n2zx) (alanine - unii:of5p57n2zx), glycine (unii: te7660xo1c) (glycine - unii:te7660xo1c), arginine (unii: 94zla3w45f) (arginine - unii:94zla3w45f), proline (unii: 9dlq4ciu6v) (proline - unii:9dlq4ciu6v), glutamic acid (unii: 3kx376gy7l) (glutamic acid - unii:3kx376gy7l), serine (unii: 452vly9402) (serine - unii:452vly9402), aspartic acid (unii: 30kyc7miai) (aspartic acid - unii:30kyc7miai), tyrosine (unii: 42hk56048u) (tyrosine - unii:42hk56048u) - valine 1.44 g in 100 ml - prosol is indicated as a source of amino acids for patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. prosol may be used to treat negative nitrogen balance in patients. the use of prosol is contraindicated in: risk summary limited published data with injectable amino acids solutions, including prosol in pregnant women are not sufficient to inform a drug associated risk for adverse developmental outcomes. however, malnutrition in pregnant women is associated with adverse maternal and fetal outcomes [see clinical considerations]. animal reproduction studies have not been conducted with injectable amino acids solutions, including prosol. the background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. however, the background risk in the u.s. general population of major birth defects is 2 to 4% and of miscarriage is 15 to 20% of clinically recognized pregnancies. clinical considerations disease-associated maternal and/or embryo-fetal risk severe malnutrition in pregnant women is associated with preterm delivery, low birth weight, intrauterine growth restriction, congenital malformations and perinatal mortality. parenteral nutrition should be considered if a pregnant woman’s nutritional requirements cannot be fulfilled by oral or enteral intake. risk summary there are no data available to assess the presence of injectable amino acids, including prosol in human milk, the effects of prosol on the breastfed infant or the effects on milk production. the lack of clinical data during lactation precludes a clear determination of the risk of prosol to a child during lactation; therefore, the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for prosol and any potential adverse effects on the breastfed child from prosol or from the underlying maternal condition. neonates, especially premature infants with low birth weight, are at increased risk of developing hypo- or hyperglycemia and therefore need close monitoring during treatment with intravenous glucose solutions to ensure adequate glycemic control in order to avoid potential long term adverse effects [see dosage and administration (2.7)]. plasma electrolyte concentrations should be closely monitored in the pediatric patients who may have impaired ability to regulate fluids and electrolytes. hyperammonemia is of special significance in infants (birth to two years). this reaction appears to be related to a deficiency of the urea cycle amino acids of genetic or product origin. it is essential that blood ammonia be measured frequently in infants [see warnings and precautions (5.7)]. because of immature renal function, preterm infants receiving prolonged parenteral nutrition treatment with prosol may be at risk of aluminum toxicity [see warnings and precautions (5.8)]. patients, including pediatric patients, may be at risk for pnald [see warnings and precautions (5.9)]. clinical studies with prosol have not been performed to determine whether subjects aged 65 and over respond differently from other younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or drug therapy. in patients with impaired renal function, parenteral nutrition solutions containing prosol should be administered with caution. frequent clinical evaluation and laboratory tests to monitor renal function such as serum electrolytes (especially phosphate and potassium) and fluid balance should be conducted [see dosage and administration (2.6) , and warnings and precautions (5.10)]. in patients with impaired liver function, parenteral nutrition solutions containing prosol should be administered starting at the low end of the dosing range [see dosage and administration (2.5)]. frequent clinical evaluation and laboratory tests to monitor liver function such as bilirubin and liver function parameters should be conducted [see warnings and precautions (5.7) ].

Estados Unidos - inglês - NLM (National Library of Medicine)

bioactive nutritional, inc. - .alpha.-ketoglutaric acid (unii: 8id597z82x) (.alpha.-ketoglutaric acid - unii:8id597z82x), isoleucine (unii: 04y7590d77) (isoleucine - unii:04y7590d77), arginine (unii: 94zla3w45f) (arginine - unii:94zla3w45f), levocarnitine (unii: 0g389fzz9m) (levocarnitine - unii:0g389fzz9m), leucine (unii: gmw67qnf9c) (leucine - unii:gmw67qnf9c), ornithine (unii: e524n2ixa3) (ornithine - unii:e524n2ixa3), valine (unii: hg18b9yrs7) (valine - unii:hg18b9yrs7), estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z8 - .alpha.-ketoglutaric acid 3 [hp_x] in 1 ml - for temporary relief of muscular exhaustion, debility after exercise and lowered vitality in the female after exercise. for temporary relief of muscular exhaustion, debility after exercise and lowered vitality in the female after exercise.

Filipinas - inglês - FDA (Food And Drug Administration)

shalaks pharmaceuticals, inc; distributor: shalaks pharmaceuticals, inc - multivitamins phosphorus , amino acids , bacillus coagulans (vet.) - syrup - formulation: each 100 ml contains: beta carotene (vitamin a) 2500000 iu cholecalciferol (vitamin d1) 250000 iu tocopherol (vitamin e).2500 iu thiamin (as hydrochloride) (vitamin b1) 1.25 g riboflavin (as sodium phosphate) (vitamin b2) 1.25 g pyridoxine (as hydrochloride) (vitamin b6) 1.25 g ascorbic acid (vitamin c). 500 mg calcium pantothenate (vitamin b5) 500 mg menadione (vitamin k) 250 mg biotin. 250 mg folic acid (vitamin b9) 250 mg inositol....... 250 mg nicotinic acid. 250 mg cyanocobalamin (vitamin b12) 250 mcg phosphorus 125 mg lysine.... 6.25 g arginine 1.5 g leucine 875 mg valine 875 mg isoleucine 500 mg threonine 500 mg methionine 250 mg tryptophan 175 mg cystine 125 mg bacillus (weizmannia) coagulans 2x105 cfu niacinamide 250 mg bacillus (weizmannia) coagulans 2 x 105 cfu

Reino Unido - inglês - MHRA (Medicines & Healthcare Products Regulatory Agency)

baxter healthcare ltd - l-leucine; l-isoleucine; l-valine; l-lysine; l-threonine; tryptophan; l-alanine; l-arginine; glycine; l-proline; l-serine; l-tyrosine; sodium acetate; dipotassium hydrogen phosphate; sodium chloride; magnesium chloride; l-phenylalanine; l-histidine; l-methionine - infusion - 7.3gram/1litre ; 6gram/1litre ; 5.8gram/1litre ; 5.8gram/1litre ; 4.2gram/1litre ; 1.8gram/1litre ; 20.7gram/1litre ; 11.5gram/1litre ; 10.3gram/1litre ; 6.8gram/1litre ; 5gram/1litre ; 400mg/1litre ; 6.8gram/1litre ; 5.2gram/1litre ; 1.17gram/1litre ; 1.02gram/1litre ; 5.6gram/1litre ; 4.8gram/1litre ; 4gram/1litre

Estados Unidos - inglês - NLM (National Library of Medicine)

b. braun medical inc. - histidine (unii: 4qd397987e) (histidine - unii:4qd397987e), isoleucine (unii: 04y7590d77) (isoleucine - unii:04y7590d77), leucine (unii: gmw67qnf9c) (leucine - unii:gmw67qnf9c), lysine acetate (unii: ttl6g7liwz) (lysine - unii:k3z4f929h6), methionine (unii: ae28f7pnpl) (methionine - unii:ae28f7pnpl), phenylalanine (unii: 47e5o17y3r) (phenylalanine - unii:47e5o17y3r), threonine (unii: 2zd004190s) (threonine - unii:2zd004190s), tryptophan (unii: 8duh1n11bx) (tryptophan - unii:8duh1n11bx), valine (unii - histidine 0.25 g in 100 ml - 5.4% nephramine® (essential amino acid injection) is indicated for adult and pediatric use, in conjunction with other measures, to provide nutritional support for uremic patients, particularly when oral nutrition is infeasible or impractical. see warnings, precautions, pediatric use , special precautions in pediatric patients , and dosage and administration . nephramine® is contraindicated in patients with severe, uncorrected electrolyte and acid-base imbalance, hyperammonemia, decreased (subcritical) circulating blood volume, inborn errors of amino acid metabolism, or hypersensitivity to one or more amino acids present in the solution.

Israel - inglês - Ministry of Health

baxter healthcare distribution ltd., israel - arginine; calcium chloride dihydrate; glycine; histidine; isoleucine; l- alanine; leucine; lysine hydrochloride; magnesium chloride hexahydrate; methionine; phenylalanine; proline; serine; sodium (s) - lactate; sodium chloride; threonine; tryptophan; tyrosine; valine - solution for peritoneal dialysis - tyrosine 0.3 g/l; tryptophan 0.27 g/l; phenylalanine 0.57 g/l; threonine 0.646 g/l; serine 0.51 g/l; proline 0595 g/l; glycine 0.51 g/l; l- alanine 0.951 g/l; valine 1.393 g/l; methionine 0.85 g/l; isoleucine 0.85 g/l; leucine 1.02 g/l; histidine 0.714 g/l; arginine 1.071 g/l; sodium chloride 5.38 g/l; lysine hydrochloride 0.955 g/l; calcium chloride dihydrate 0.184 g/l; magnesium chloride hexahydrate 0.051 g/l; sodium (s) - lactate 4.480 g/l - combinations of electrolytes - combinations of electrolytes - nutritional supplement for malnourished renal failure patients (albumin concentration lower then 35 g/liter) being maintained on peritoneal dialysis.

Israel - inglês - Ministry of Health

remedix care ltd - glycine; l- alanine; l- aspartic acid; l- cysteine; l- glutamic acid; l- isoleucine; l- leucine; l- lysine; l- methionine; l- ornithine hydrochloride; l- phenylalanine; l- proline; l- serine; l- threonine; l- tryptophan; l- tyrosine; l- valine; l-arginine; l-histidine; taurine - solution for infusion - l- valine 0.76 g / 100 ml; l- tyrosine 0.045 g / 100 ml; l- tryptophan 0.2 g / 100 ml; l- threonine 0.37 g / 100 ml; taurine 0.06 g / 100 ml; l- serine 0.4 g / 100 ml; l- proline 0.3 g / 100 ml; l- phenylalanine 0.42 g / 100 ml; l- ornithine hydrochloride 0.318 g / 100 ml; l- methionine 0.24 g / 100 ml; l- lysine 1.1 g / 100 ml; l- leucine 1.0 g / 100 ml; l- isoleucine 0.67 g / 100 ml; l-histidine 0.38 g / 100 ml; glycine 0.4 g / 100 ml; l- glutamic acid 1.0 g / 100 ml; l- cysteine 0.189 g / 100 ml; l- aspartic acid 0.6 g / 100 ml; l-arginine 0.84 g / 100 ml; l- alanine 0.8 g / 100 ml - lysine - lysine - primene 10 % is indicated in 1) children and infants 2) neonates at term or premature of normal or low birth weight when oral or enteral nutrition is impossible insufficient or contraindicated.משטר מינון: 3/7/2019 שינוי בפרק 4.2 בעלון ללא שינוי ברשיון הנמוקים לבקשה: בהתאם לעלון רפרנס spc-uk ו-clinical overview

Estados Unidos - inglês - NLM (National Library of Medicine)

guna spa - calcitonin human (unii: i0io929019) (calcitonin human - unii:i0io929019), isoleucine (unii: 04y7590d77) (isoleucine - unii:04y7590d77), leucine (unii: gmw67qnf9c) (leucine - unii:gmw67qnf9c), lysine (unii: k3z4f929h6) (lysine - unii:k3z4f929h6), methionine (unii: ae28f7pnpl) (methionine - unii:ae28f7pnpl), phenylalanine (unii: 47e5o17y3r) (phenylalanine - unii:47e5o17y3r), threonine (unii: 2zd004190s) (threonine - unii:2zd004190s), tryptophan (unii: 8duh1n11bx) (tryptophan - unii:8duh1n11bx), valine - calcitonin human 6 [hp_x] in 30 ml - bone 10x 30x 200x bone fractures calcarea fluorica 12x 30x 200x bone fractures calcarea carbonica 12x 30x 200x bone fractures calcarea phosphorica 12x 30x 200x bone fractures calcitonin 6x bone fractures parathyroid gland 10x 30x 200x improves bone repair temporary relief of symptoms related weak bones such as: - frequent and slow-healing fractures - sharp and dull bone pain take 15 minutes before meals